Nanostructured lipidic materials for controlled drug release
Innovative lipidic materials offering controlled release of hydrophobic drugs by tuning nanostructures, enhancing stability and bioavailability. Ideal for pharmaceuticals needing precise release profiles.
Overview
Monash University presents an advanced solution in drug delivery through nanostructured lipidic materials. This technology focuses on encapsulating hydrophobic active ingredients within lipidic liquid crystalline mesophases, enhancing their stability and bioavailability. By leveraging the self-assembling properties of lipids, this system offers diffusion-controlled release tailored to specific timelines. This makes it highly suitable for pharmaceuticals requiring precise release profiles.
Technical specifications
- Encapsulation and Release Control: Utilizes lipidic mesophases to provide diffusion-controlled release of hydrophobic compounds.
- Nanostructure Tuning: Formulation can be adjusted to control release rates precisely using microfluidic manufacturing techniques.
- Biodegradable Materials: Uses bioderived, biodegradable lipids that can be coated with polymers like chitin or polypeptides.
- Manufacturing Process: Particle sizes are controlled through flow rate adjustments in microfluidic or confined impinging jet mixers, with characterization via small angle X-ray scattering (SAXS) and cryoSEM.
Technology readiness level
This technology is at TRL 4, having been validated under laboratory conditions with plans for further validation in controlled settings. The upcoming 18-month research plan aims to refine the formulation and quantify release rates, setting the stage for broader applications and potential commercialization.
About Monash University, Melbourne
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.
Inquire about this partnering listing
Industry applications
delivered to your inbox.